` Comparison: BOD vs LLY - Alpha Spread

BOD
vs
LLY

Over the past 12 months, BOD has underperformed LLY, delivering a return of 0% compared to the LLY's +14% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
BOD
LLY
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

BOD Intrinsic Value
HIDDEN
Show
LLY Intrinsic Value
HIDDEN
Show
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
BOD Australia Ltd
ASX:BOD
0.024 AUD
Eli Lilly and Co
NYSE:LLY
1 043.485 USD
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
BOD, LLY

BOD
LLY
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
BOD Australia Ltd
Revenue
Eli Lilly and Co
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
BOD, LLY

BOD
LLY
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
BOD Australia Ltd
ASX:BOD
Eli Lilly and Co
NYSE:LLY
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

BOD
47%
LLY
83%
LTM 3Y Avg 5Y Avg 10Y Avg
BOD Australia Ltd
Eli Lilly and Co

Operating Margin

BOD
11.6%
LLY
45.6%
LTM 3Y Avg 5Y Avg 10Y Avg
BOD Australia Ltd
Eli Lilly and Co

Net Margin

BOD
12%
LLY
31.7%
LTM 3Y Avg 5Y Avg 10Y Avg
BOD Australia Ltd
Eli Lilly and Co

FCF Margin

BOD
43.3%
LLY
9.9%
LTM 3Y Avg 5Y Avg 10Y Avg
BOD Australia Ltd
Eli Lilly and Co

ROE

BOD
-4.9%
LLY
108.7%
LTM 3Y Avg 5Y Avg 10Y Avg
BOD Australia Ltd
Eli Lilly and Co

ROA

BOD
10.6%
LLY
21.3%
LTM 3Y Avg 5Y Avg 10Y Avg
BOD Australia Ltd
Eli Lilly and Co

ROIC

BOD
-9.4%
LLY
27.6%
LTM 3Y Avg 5Y Avg 10Y Avg
BOD Australia Ltd
Eli Lilly and Co

ROCE

BOD
-4.8%
LLY
47.5%
LTM 3Y Avg 5Y Avg 10Y Avg
BOD Australia Ltd
Eli Lilly and Co

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
BOD, LLY

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BOD, LLY

Performance Gap Between BOD and LLY
HIDDEN
Show

Performance By Year
BOD, LLY

Loading
BOD
LLY
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare BOD to other stocks
JNJ
Johnson & Johnson
ROG
Roche Holding AG
AZN
AstraZeneca PLC
NOVN
Novartis AG
Custom
Choose any stock
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett